Table 3.

Treatment-related adverse events in 38 patients.

	Grade 1	Grade 2	Grade 3	Grade 4	Total
Adverse events	n (%)	n (%)	n (%)	n	n (%)
Abdominal pain	6 (16%)	1 (3%)	0 (0%)	0	7 (18%)
ALT increased	4 (11%)	1 (3%)	2 (5%)	0	7 (18%)
Alopecia	3 (8%)	0 (0%)	0 (0%)	0	3 (8%)
Anemia	2 (5%)	2 (5%)	0 (0%)	0	4 (10%)
Anorexia	11 (29%)	4 (11%)	1 (3%)	0	16 (47%)
Arthralgia	3 (8%)	4 (11%)	0 (0%)	0	7 (18%)
AST increased	5 (13%)	1 (3%)	1 (3%)	0	7 (18%)
Blurred vision	4 (11%)	0 (0%)	0 (0%)	0	4 (12%)
Chills	13 (34%)	7 (18%)	1 (3%)	0	21 (55%)
Constipation	4 (11%)	3 (8%)	0 (0%)	0	7 (18%)
Creatinine increased	0 (0%)	4 (11%)	0 (0%)	0	4 (10%)
Dehydration	1 (3%)	4 (11%)	3 (8%)	0	8 (21%)
Diarrhea	14 (37%)	5 (13%)	2 (5%)	0	21 (55%)
Dizziness	5 (13%)	0 (0%)	0 (0%)	0	5 (13%)
Dry mouth	7 (18%)	1 (3%)	0 (0%)	0	8 (21%)
Dysgeusia	6 (16%)	0 (0%)	0 (0%)	0	6 (16%)
Dyspepsia	2 (5%)	2 (5%)	0 (0%)	0	4 (10%)
Edema limbs	4 (11%)	2 (5%)	0 (0%)	0	6 (16%)
Ejection fraction decreased	0 (0%)	2 (5%)	1 (3%)	0	3 (8%)
Prolonged QTc	6 (16%)	2 (5%)	0 (0%)	0	8 (21%)
Encephalopathy	0 (0%)	0 (0%)	1 (3%)	0	1 (3%)
Fatigue	8 (21%)	12 (32%)	2 (5%)	0	22 (57%)
Fever	12 (32%)	12 (32%)	1 (3%)	0	25 (66%)
Headache	6 (16%)	4 (11%)	2 (5%)	0	12 (32%)
Lymphocyte count decreased	0 (0%)	1 (3%)	1 (3%)	0	2 (5%)
Malaise	4 (11%)	2 (5%)	0 (0%)	0	6 (16%)
Mucositis oral	0 (0%)	0 (0%)	1 (3%)	0	1 (3%)
Myalgia	13 (34%)	1 (3%)	0 (0%)	0	14 (37%)
Nausea	16 (42%)	6 (16%)	2 (5%)	0	24 (63%)
Neutrophil count decreased	0 (0%)	1 (3%)	1 (3%)	0	2 (5%)
Sigmoid polyp	0 (0%)	1 (3%)	0 (0%)	0	1 (3%)
Squamous cell carcinoma	0 (0%)	3 (8%)	0 (0%)	0	3 (8%)
Palmar–plantar erythrodysesthesia	2 (5%)	2 (5%)	0 (0%)	0	4 (10%)
Pruritus	7 (18%)	1 (3%)	0 (0%)	0	8 (21%)
Rash	9 (24%)	8 (21%)	5 (13%)	0	22 (58%)
Retinopathy	2 (5%)	0 (0%)	0 (0%)	0	2 (5%)
Seizure	0 (0%)	0 (0%)	1 (3%)	0	1 (3%)
Sepsis	0 (0%)	0 (0%)	1 (3%)	0	1 (3%)
Vomiting	7 (18%)	1 (3%)	0 (0%)	0	8 (21%)
Weight loss	3 (8%)	3 (8%)	0 (0%)	0	6 (16%)